OncoMatch/Clinical Trials/NCT05576480
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
Is NCT05576480 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Penpulimab and CAPEOX for rectal cancer.
Treatment: Penpulimab · CAPEOX — The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally advanced rectal cancer. The main question it aims to answer is the role of immune checkpoint inhibitors in the neoadjuvant treatment of MSS rectal cancer. Participants will receive neoadjuvant treatment of SCRT sequential Penpulimab in combination with CAPEOX. Participants will undergo a clinical re-staging assessment at the end of neoadjuvant therapy to determine whether to adopt a watch-and-wait strategy or undergo radical surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic radiotherapy
Previous treatment with pelvic radiotherapy
Cannot have received: rectal cancer surgery
Previous treatment with rectal cancer surgery
Cannot have received: chemotherapy
Previous treatment with chemotherapy
Cannot have received: targeted therapy
Previous treatment with targeted therapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors (including but not limited to PD-1, PD-L1, CTLA-4)
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify